• Publications
  • Influence
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
TLDR
APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80. Expand
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
TLDR
It is demonstrated that there was a highly significant association of apolipoprotein E type 4 allele (APOE-epsilon 4) and late-onset familial Alzheimer disease. Expand
Patterns of brain activation in people at risk for Alzheimer's disease.
TLDR
Patterns of brain activation during tasks requiring memory differ depending on the genetic risk of Alzheimer's disease and may predict a subsequent decline in memory. Expand
Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways
TLDR
Using a sensitive qRT-PCR platform, experimental validation is used to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity. Expand
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
TLDR
Data support the involvement of ApoE epsilon 4 in the pathogenesis of late-onset familial and sporadic AD and suggest it may operate as a susceptibility gene (risk factor) for the clinical expression of AD. Expand
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
TLDR
A protective effect of the ε2 allele, in addition to the dose effect ofThe ε4 allele in sporadic AD, is demonstrated, which further support the direct involvement of APOE in the pathogenesis of AD. Expand
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
TLDR
Differences in the two isoforms in complexing with the beta/A4 peptide may be involved in the pathogenesis of the intra- and extracellular lesions of Alzheimer disease. Expand
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
TLDR
Neocortical neurofibrillary tangle densities were substantially correlated with dementia severity, and to a greater degree than was true for senile plaque densities, and the order of the strength of relationships between densities of histologic markers and dementia severity in AD is neuroFibrillary tangles greater than cored senile plaques greater than total senile Plaques. Expand
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
TLDR
Using phylogenetic analysis, a polymorphic poly-T variant, rs10524523, in the translocase of outer mitochondrial membrane 40 homolog (TOMM40) gene is identified that provides greatly increased precision in the estimation of age of LOAD onset for APOE ɛ3 carriers. Expand
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
TLDR
Exploratory analyses suggested that APOE ɛ4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas apolipoprotein E (APOE) genotype carriers showed no improvement and some decline was noted. Expand
...
1
2
3
4
5
...